Santos Lifts 3Q Revenue 7% Amid Higher Commodity Prices
By Stuart Condie
SYDNEY--Australian oil and gas producer Santos said sales revenue rose by 7% in the September quarter compared with the prior three months, reflecting higher crude-oil volumes and increased commodity prices for all its products.
Santos on Thursday reported quarterly sales revenue of $1.44 billion, up from $1.34 billion in its fiscal second quarter. The rise came against a backdrop of a 2% quarterly rise in oil and gas production to 23.2 million barrels of oil equivalent.
Santos said its free cash flow was around $470 million in the quarter.
"Free cash flow of $1.6 billion year-to-date positions the company well to deliver shareholder returns, backfill and sustain our existing business, while also investing in our major projects," Chief Executive Kevin Gallagher said.
Santos made no changes to guidance for annual production, sales, capital expenditure and costs, but said it would update its outlook after completing the previously announced selldown of its stake in the PNG LNG liquefied natural-gas project.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
October 18, 2023 19:19 ET (23:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks